IBA - Regulated Information
01 Agosto 2024 - 11:00AM
UK Regulatory
IBA - Regulated Information
(Article 14, paragraph 1 of the law of 2
May 2007 on the disclosure of major holdings)
Louvain-la-Neuve, Belgium, August 1st,
2024 06:00
Summary of the notification
IBA (Ion Beam Applications), the world’s leading
provider of proton therapy solutions for the treatment of cancer,
announces that it has to issue a transparency notification, in
accordance with Article 14, al. 1 of the Transparency Law of May 2,
2007 on disclosure of major holdings, further to the notification
received on July 30, 2024.
In its notification, FMR LLC indicated that
following an acquisition or disposal of securities or voting
rights. Its total participation in IBA SA decreased and its
participation in IBA shares with voting rights crossed the
threshold of 1% on 25/07/2024.
Content of the notification
- Reason for the notification: Acquisition or disposal of
securities or voting rights
- Notification by: A parent company or controlling
person
- Persons subject to the notification
requirement:
- Date on which the threshold is crossed: 25/07/2024
- Threshold crossed (in %) : 1%
- Denominator : 40.595.290
- Notified details: (extract of the received notification
form)
- Full chain of controlled undertakings through which the
holding is effectively held
FIAM LLC is controlled by FIAM Holdings LLC.FIAM
Holdings LLC, Fidelity Management & Research Company LLC are
controlled by FMR LLC.FMR LLC is not a controlled undertaking
The holdings attributed to the entities
mentioned in heading 10 arise from holdings of various undertakings
for collective investment that are managed by FIAM LLC and Fidelity
Management & Research Company LLC each of which are entities
that are subsidiaries of and controlled by FMR LLC. The entities
mentioned in heading 10 are the discretionary investment managers
and exercise the voting rights at their discretion in the absence
of specific instructions.
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 2.000 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
For further information, please
contact:
Valérie Van Impe
Paralegal
+32479267809
legal@iba-group.com
- 20240801-IBA-FMR LLC_transparency EN
Ion Beam Applications (EU:IBAB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Ion Beam Applications (EU:IBAB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024